WHAT’S KNOWN?
- Autologous hematopoietic stem cell transplantation (AHSCT) was first used as frontline, consolidative treatment for aggressive non-Hodgkin lymphoma (NHL) in the early ‘90s.
- In selected centres, upfront AHSCT has also been considered a feasible form of management for poor risk patients.
-There is scarce information available in regards to the survival outcome of NHL in South East Asia regions. Reports on the outcome of high dose therapy followed by AHSCT were mainly from developed countries.